Cargando…

Defining levels of dengue virus serotype-specific neutralizing antibodies induced by a live attenuated tetravalent dengue vaccine (TAK-003)

The four dengue virus serotypes (DENV1-4) infect several hundred million people each year living in tropical and sub-tropical regions. Clinical development of DENV vaccines is difficult because immunity to a single serotype increases risk of severe disease during a second infection with a new seroty...

Descripción completa

Detalles Bibliográficos
Autores principales:	White, Laura J., Young, Ellen F., Stoops, Mark J., Henein, Sandra R., Adams, Elizabeth C., Baric, Ralph S., de Silva, Aravinda M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7990299/ https://www.ncbi.nlm.nih.gov/pubmed/33711074 http://dx.doi.org/10.1371/journal.pntd.0009258

Ejemplares similares

Effect of the Tetravalent Dengue Vaccine TAK-003 on Sequential Episodes of Symptomatic Dengue
por: Sáez-Llorens, Xavier, et al.
Publicado: (2023)

Clinical Safety Experience of TAK-003 for Dengue Fever: A New Tetravalent Live Attenuated Vaccine Candidate
por: Patel, Sanjay S, et al.
Publicado: (2022)

Bridging the immunogenicity of a tetravalent dengue vaccine (TAK-003) from children and adolescents to adults
por: LeFevre, Inge, et al.
Publicado: (2023)

97. Tetravalent Dengue Vaccine (TAK-003) Development Program: A Bird’s Eye View
por: Tricou, Vianney, et al.
Publicado: (2021)

A tetravalent live attenuated dengue virus vaccine stimulates balanced immunity to multiple serotypes in humans
por: Nivarthi, Usha K., et al.
Publicado: (2021)

Stimulation of B Cell Immunity in Flavivirus-Naive Individuals by the Tetravalent Live Attenuated Dengue Vaccine TV003
por: Tu, Huy A., et al.
Publicado: (2020)

Induction of Neutralizing Antibodies against Four Serotypes of Dengue Viruses by MixBiEDIII, a Tetravalent Dengue Vaccine
por: Zhao, Hui, et al.
Publicado: (2014)

Natural Strain Variation and Antibody Neutralization of Dengue Serotype 3 Viruses
por: Wahala, Wahala M. P. B., et al.
Publicado: (2010)

Dengue virus 4/2 envelope domain chimeric virus panel maps type-specific responses against dengue serotype 2
por: Zhu, Deanna R., et al.
Publicado: (2023)

Human dengue virus serotype 2 neutralizing antibodies target two distinct quaternary epitopes
por: Gallichotte, Emily N., et al.
Publicado: (2018)

Three-year Efficacy and Safety of Takeda’s Dengue Vaccine Candidate (TAK-003)
por: Rivera, Luis, et al.
Publicado: (2021)

Specificity and Breadth of the Neutralizing Antibody Response to a Live-Attenuated Tetravalent Dengue Vaccine
por: DeMaso, Christina R, et al.
Publicado: (2022)

Transplantation of a quaternary structure neutralizing antibody epitope from dengue virus serotype 3 into serotype 4
por: Widman, Douglas G., et al.
Publicado: (2017)

Assessing the Diversity and Stability of Cellular Immunity Generated in Response to the Candidate Live-Attenuated Dengue Virus Vaccine TAK-003
por: Waickman, Adam T., et al.
Publicado: (2019)

Nanoparticle delivery of a tetravalent E protein subunit vaccine induces balanced, type-specific neutralizing antibodies to each dengue virus serotype
por: Metz, Stefan W., et al.
Publicado: (2018)

In a randomized trial, the live attenuated tetravalent dengue vaccine TV003 is well-tolerated and highly immunogenic in subjects with flavivirus exposure prior to vaccination
por: Whitehead, Stephen S., et al.
Publicado: (2017)

Immunogenicity and safety of concomitant and sequential administration of yellow fever YF-17D vaccine and tetravalent dengue vaccine candidate TAK-003: A phase 3 randomized, controlled study
por: Tricou, Vianney, et al.
Publicado: (2023)

Development and Characterization of a Reverse Genetic System for Studying Dengue Virus Serotype 3 Strain Variation and Neutralization
por: Messer, William B., et al.
Publicado: (2012)

Current Development and Challenges of Tetravalent Live-Attenuated Dengue Vaccines
por: Hou, Jue, et al.
Publicado: (2022)

Tracking the polyclonal neutralizing antibody response to a dengue virus serotype 1 type-specific epitope across two populations in Asia and the Americas
por: Andrade, Daniela V., et al.
Publicado: (2019)

1051. Characterization of Immune Responses to a Live-Attenuated Tetravalent Dengue Vaccine
por: Braun, Ralph, et al.
Publicado: (2021)

An open-label, Phase 3 trial of TAK-003, a live attenuated dengue tetravalent vaccine, in healthy US adults: immunogenicity and safety when administered during the second half of a 24-month shelf-life
por: Patel, Sanjay S., et al.
Publicado: (2023)

Challenges to the Design of Clinical Trials for Live-Attenuated Tetravalent Dengue Vaccines
por: Russell, Philip K., et al.
Publicado: (2016)

Efficacy of a Dengue Vaccine Candidate (TAK-003) in Healthy Children and Adolescents 2 Years after Vaccination
por: López-Medina, Eduardo, et al.
Publicado: (2020)

Dengue virus-like particles mimic the antigenic properties of the infectious dengue virus envelope
por: Metz, Stefan W., et al.
Publicado: (2018)

Immunogenicity and safety of a tetravalent dengue vaccine in dengue-naïve adolescents in Mexico City
por: Biswal, Shibadas, et al.
Publicado: (2021)

A live dengue virus vaccine carrying a chimeric envelope glycoprotein elicits dual DENV2-DENV4 serotype-specific immunity
por: Young, Ellen, et al.
Publicado: (2023)

Lack of Durable Cross-Neutralizing Antibodies Against Zika Virus from Dengue Virus Infection
por: Collins, Matthew H., et al.
Publicado: (2017)

Analysis of Individuals from a Dengue-Endemic Region Helps Define the Footprint and Repertoire of Antibodies Targeting Dengue Virus 3 Type-Specific Epitopes
por: Andrade, Daniela V., et al.
Publicado: (2017)

Epitope Addition and Ablation via Manipulation of a Dengue Virus Serotype 1 Infectious Clone
por: Gallichotte, Emily N., et al.
Publicado: (2017)

Dengue Reporter Virus Particles for Measuring Neutralizing Antibodies against Each of the Four Dengue Serotypes
por: Mattia, Kimberly, et al.
Publicado: (2011)

A tetravalent dengue nanoparticle stimulates antibody production in mice
por: Silva, Elisângela F, et al.
Publicado: (2012)

Genetic epidemiology of dengue viruses in phase III trials of the CYD tetravalent dengue vaccine and implications for efficacy
por: Rabaa, Maia A, et al.
Publicado: (2017)

CYD Tetravalent Dengue Vaccine Performance by Baseline Immune Profile (Monotypic/Multitypic) in Dengue-Seropositive Individuals
por: DiazGranados, Carlos A, et al.
Publicado: (2020)

Influence of FcγRIIa-Expressing Cells on the Assessment of Neutralizing and Enhancing Serum Antibodies Elicited by a Live-Attenuated Tetravalent Dengue Vaccine
por: Byers, Anthony M., et al.
Publicado: (2015)

A Rapid Immunization Strategy with a Live-Attenuated Tetravalent Dengue Vaccine Elicits Protective Neutralizing Antibody Responses in Non-Human Primates
por: Ambuel, Yuping, et al.
Publicado: (2014)

Neutralization of Dengue Virus Serotypes by Sera from Dengue-Infected Individuals Is Preferentially Directed to Heterologous Serotypes and Not against the Autologous Serotype Present in Acute Infection
por: Auerswald, Heidi, et al.
Publicado: (2021)

Genetic Variation between Dengue Virus Type 4 Strains Impacts Human Antibody Binding and Neutralization
por: Gallichotte, Emily N., et al.
Publicado: (2018)

Induction of Neutralizing Antibody Response against Four Dengue Viruses in Mice by Intramuscular Electroporation of Tetravalent DNA Vaccines
por: Prompetchara, Eakachai, et al.
Publicado: (2014)

Antigenic Variation of the Dengue Virus 2 Genotypes Impacts the Neutralization Activity of Human Antibodies in Vaccinees
por: Martinez, David R., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_g49j5kdmfd2og5ma11e5ne9gtp